 |
|
Drug compound leads to death of ovarian cancer cells resistant to chemotherapy
April 18, 2008In a discovery that may be useful for maintaining remission in chemo-resistant ovarian cancer, Yale scientists report that pre-clinical studies have shown the drug compound NV-128 can induce the death of ovarian cancer cells by halting the activation of a protein pathway called mTOR.
Gil Mor, M.D., associate professor in the Department of Obstetrics, Gynecology & Reproductive Sciences at Yale School of Medicine, and associate research scientist Ayesha Alvero, M.D. presented the data April 15 during an oral presentation at the annual meeting of the American Association for Cancer Research.
In cancer cells, mTOR signals enhance tumor growth and may be associated with resistance to conventional therapies. Inhibition of mTOR could shut down many of these survival pathways, including proteins that protect the mitochondria of cancer cells.
NV-128, developed by Novogen Limited, holds promise as a more targeted therapy for ovarian cancer because it works differently from traditional therapies that are dependent on enzymes known as caspases to trigger cell death. Therapies using caspases to kill cancer cells can be ineffective in chemo-resistant cancer cells due to mutations that short-circuit signals that trigger cancer cell death.
"We consider that the capacity of NV-128 to trigger caspase-independent cell death, in otherwise chemoresistant ovarian cancer cells, opens new possibilities for the use of NV-128 as a potential addition to conventional chemotherapy targeting ovarian cancer cells," said Mor.
In the context of developing therapies for late stage ovarian cancer, Mor said, the finding may be "a key step to the development of alternative targeted therapy for patients with cancer recurrence."
Yale University
NV-128, developed by Novogen Limited, holds promise as a more targeted therapy for ovarian cancer because it works differently from traditional therapies that are dependent on enzymes known as caspases to trigger cell death. Therapies using caspases to kill cancer cells can be ineffective in chemo-resistant cancer cells due to mutations that short-circuit signals that trigger cancer cell death.
"We consider that the capacity of NV-128 to trigger caspase-independent cell death, in otherwise chemoresistant ovarian cancer cells, opens new possibilities for the use of NV-128 as a potential addition to conventional chemotherapy targeting ovarian cancer cells," said Mor.
In the context of developing therapies for late stage ovarian cancer, Mor said, the finding may be "a key step to the development of alternative targeted therapy for patients with cancer recurrence."
Yale University
Ovarian Cancer Current Events and Ovarian Cancer News RSSNew study questions benefits of elective removal of ovaries during hysterectomy
Removal of the ovaries (bilateral oophorectomy) while performing a hysterectomy is common practice to prevent the subsequent development of ovarian cancer.
UAB Cancer Center, Urologists Affirm Men Should Take Lead in Deciding to Test for Prostate Cancer
Men who undergo prostate-cancer screening should discuss with a doctor the uncertainties, risks and benefits of the test before it is performed, says Edward Partridge, M.D., president-elect of the American Cancer Society (ACS) National Board of Directors and director of the University of Alabama at Birmingham (UAB) Comprehensive Cancer Center.
Dietary factors influence ovarian cancer survival rates
2009 estimates projected that in the United States alone 21,550 new cases of ovarian cancer would be diagnosed and 14,600 women would die of the disease.
Molecular pathways linked to sex, age affect outcomes in lung cancer
The biology of lung cancer differs from one patient to the next, depending on age and sex, according to scientists at Duke University Medical Center. The findings may help explain why certain groups of patients do better than others, even though they appear to have the same disease.
Single gene mutation induces endometrial cancer
A mutation in a single gene can cause endometrial cancer that is responsive to a specific drug therapy, researchers at UT Southwestern Medical Center have found in an animal study.
Disarming specialized stem cells might combat deadly ovarian cancer
Eliminating cancer stem cells (CSCs) within a tumor could hold the key to successful treatments for ovarian cancer, which has been notoriously difficult to detect and treat, according to new findings published this week in the journal Oncogene by Yale School of Medicine researchers.
Assessing lead time of selected ovarian cancer biomarkers
Concentrations of the biomarkers CA125, human epididymis protein 4 (HE4), and mesothelin began to rise 3 years before clinical diagnosis of ovarian cancer, according to a new study published online December 30 in the Journal of the National Cancer Institute.
Research suggests link between infertility, low egg reserve, and breast/ovarian cancer gene (BRCA1)
A New York Medical College physician who specializes in restoring or preserving fertility in female cancer patients has discovered a possible link between the presence of breast cancer genes and infertility.
Tracking new cancer-killing particles with MRI
Researchers at Rice University and Baylor College of Medicine (BCM) have created a single nanoparticle that can be tracked in real time with MRI as it homes in on cancer cells, tags them with a fluorescent dye and kills them with heat.
Scientists use nanosensors for first time to measure cancer biomarkers in blood
A team led by Yale University researchers has used nanosensors to measure cancer biomarkers in whole blood for the first time.
More Ovarian Cancer Current Events and Ovarian Cancer News Articles
 |
12 Ribbon Cancer Awareness Charm Chamrs Findings Jewelry Making Bracelets Fundraising (Teal) by Knextion 12 piece pack charms. Great for jewelry making, fundraising projects or gift favors! |
 |
Beating Ovarian Cancer: How To Overcome The Odds And Reclaim Your Life by Chris Bledy (Author) A diagnosis of Ovarian Cancer does not have to be a death sentence. Recent advances in medicine have made this once incurable disease treatable and manageable. You can beat advanced and even recurring, ovarian cancer. Simple but significant lifestyle changes can produce big results when it comes to healing. |
 |
Ovarian Cancer Awareness "Unite to Fight" Wristband Adult Size by sci Ovarian Cancer Awareness "Unite To Fight" Wristband adult size |
 |
Ovarian Cancer Awareness 8" Ribbon Car Magnet by sci Ovarian Cancer Awareness 8" Ribbon Car Magnet |
 |
A Guide to Survivorship for Women with Ovarian Cancer (A Johns Hopkins Press Health Book) by F. J. Montz MD KM FACOG FACS (Author), Robert E. Bristow MD FACOG (Author), Paula J. Anastasia RN MN OCN (Assistant) This comprehensive guide to ovarian cancer offers a wealth of information to ease the physical, emotional, and psychic suffering of women with the disease. The authors -- two Johns Hopkins gynecologic oncologists and a gynecologic-oncology clinical nurse -- put particular emphasis on the concept of "survivorship," or living life well in the face of daunting uncertainties. They stress the importance of self-determination: the right of each patient to be informed, involved, and in control of her care. Up-to-date information on diagnosis and treatment, including surgery, chemotherapy, radiation, pain management, and alternative therapies, forms the core of the book. But the authors' immense clinical experience also means they understand what women worry about and care about, and... |
 |
L'Oréal Paris Color of Hope OCRF (Ovarian Cancer Research Fund) Fundraising Sterling Silver Pavé CZ Bracelet by Netaya Sterling beauty with an equally beautiful message. Its new, its exclusive and its absolutely beautiful. LOreal Paris is proud to present the Color of Hope Bracelet, a fundraising campaign, with 100% of all net profits ($5.00 per bracelet) benefiting The Ovarian Cancer Research Fund (OCRF). Whether viewed as a circle representing life, endurance, love or seen as an "O" for ovarian cancer, the bracelet is a simple way for women everywhere to visibly and tangibly help in the fight against one of the world's most deadly of women's cancers. The exclusive sterling silver Color of Hope bracelet features a rolo design chain with an "O" toggle clasp, adorned with pave cubic zirconias to give a beautiful brilliance. And to ensure that all women can adorn their wrists, the bracelet... |
 |
Ovarian Cancer Awareness Ribbon Magnet by SupportStore Buy the "Ovarian Cancer Awareness" Teal Ribbon Car Magnet. Our Ovarian Cancer Awareness Ribbon Magnet is manufactured and printed in the USA. We print on premium quality, super-thick (.030) magnetic material with UV protected inks. Be sure to remove, clean and reposition your magnet weekly. We also carry "Ovarian Cancer Awareness" Rubber Bracelets. Allow us to create custom "Ovarian Cancer Awareness" Rubber Bracelets and Ribbon Magnets for your organization or next event. |
 |
Johns Hopkins Patients' Guide to Ovarian Cancer (Johns Hopkins Patients' Guides) by Ritu Salani (Author), Robert E. Bristow (Author) The Johns Hopkins Patients Guide to Ovarian Cancer is a concise, easy-to-follow how to guide that puts you on a path to wellness by explaining ovarian cancer treatments from start to finish. It guides you through the overwhelming maze of treatment decisions, simplifies the complicated schedule that lies ahead, and provides valuable tools to help you to put together your plan of care. Empower yourself with accurate, understandable information that will give you the ability to confidently participate in the decision making about your care and treatment. |
 |
Ovarian Cancer Awareness Ribbon Magnet by Magnet Inc. Model: M-LR-OVAR; Ovarian Cancer Awareness 2 in 1 Ribbon Magnet. High Quality UV protected printed vinyl ribbons backed with thick .30 mil magnetic material. Great fundraiser for awareness organizations, schools, churches, or your fundraiser group. Dimensions: 3 7/8" x 8" |
 |
Ovarian Cancer Journeys: Survivors Share Their Stories To Help Others by Ayala Miron (Author) "All of the research has reinforced that ovarian cancer is not a silent disease as was once thought and as is shown quite eloquently in this collection of stories.... The value of this collection of stories is that it helps raise awareness about symptoms, need for patient persistence, and the importance of being treated by a gynecologic oncologist." Barbara A. Goff, MD Professor and Co-Director, Division of Gynecologic Oncology University of Washington School of Medicine Women of ages 17 to 78 join to tell their true stories. Find out about the lessons they have learned along their ovarian cancer journeys; from symptoms to diagnosis, trough treatments, and survival. Ovarian cancer facts: Occurs in 1 out of 57 women 89% have symptoms at the early stages... |
| © 2010 BrightSurf.com |